Metastatic Castration-Resistant Prostate Cancer: Two Case Reports of Dramatic Response with Abiraterone Acetate in Patients Heavily Pretreated with Chemotherapy

Metastatic castration-resistant prostate cancer (mCRPC) with visceral involvement requires new, effective and safe treatments after chemotherapy failure. The CYP17A1 inhibitor abiraterone acetate has been approved as a treatment for mCRPC, both after docetaxel chemotherapy and more recently for pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Dupuy, Laura, Long, Jérôme, Ranchoup, Yves
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2011
Materias:
Published online: June, 2013
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3725023/
https://www.ncbi.nlm.nih.gov/pubmed/23898269
http://dx.doi.org/10.1159/000353131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3725023/
https://www.ncbi.nlm.nih.gov/pubmed/23898269
http://dx.doi.org/10.1159/000353131

Ejemplares similares